IDEX (IEX) Reports Q1 2026 Earnings Results
IDEX (IEX) reported 5% organic sales growth in Q1 2026, with strong performance in Health & Science Technologies and Fluid & Metering Technologies segments. Adjusted EBITDA margin expanded to 26%, driven by productivity and pricing improvements, though free cash flow was slightly lower than the previous year. The company also highlighted increased backlog visibility and continued share repurchases.
Topics: backlog dividend payments earnings EBITDA free cash flow orders growth sales growth